SMC® technology allows researchers to push the limits of biomarker quantification, in some cases achieving single femtogram/mL detection. Here, we will present an overview of the SMC® technology and provide a case study for custom assay development.
For Research Use Only. Not For Use In Diagnostic Procedures.
Immunoassay Platform Solutions Specialist
Since 2016, Shane has covered immunoassay platforms, including ELISAs, MILLIPLEX® multiplex assays using the Luminex® xMAP® system, and the Single Molecule Counting (SMC®) platform, in the New York City metro area. Prior to this role, he was a research scientist at Memorial Sloan Kettering Cancer Center. Shane’s background is in immunology, and he did his graduate studies at Columbia University, followed by a post-doctoral fellowship at the University of Chicago.
Former Head of Custom Assays & Sample Testing Group
Sarah Hamren was the former head of the SMC® Custom Assay and Sample Testing group until 2021. She has over 30 years of experience in biopharma research and development and her past experience includes work at Chiron Corporation, Bayer Corporation’s Biotechnology division, Tethys Bioscience, and Singulex® Inc. before joining us. She is co-author on 15 peer-reviewed publications and holds 2 U.S. patents. Sarah’s experience effectively partnering with a broad array of clients has culminated in hundreds of successful biomarker assay development projects.
To continue reading please sign in or create an account.Don't Have An Account?